Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Multiple Cancers in a Patient with Systemic Sclerosis and Aggravated Interstitial Lung Disease by Chemotherapy

  • Park, Chan Kwon (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Lee, Seok Jong (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Cho, Hyung Jun (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Lee, Kyeong Soo (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kim, Sung Jun (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Cho, Gu Min (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Lee, Ha Ni (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • Received : 2012.10.23
  • Accepted : 2013.05.28
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Although the relationship between malignancy risk with systemic sclerosis (SSc) has been inconclusive, there are some previous studies for a positive correlation. Most patients with SSc have some degree of lung parenchymal involvement in the form of interstitial thickening and fibrosis. Interstitial lung disease is the most common pulmonary manifestation of SSc. Interstitial lung disease following chemotherapy (5-fluorouracil, leucovorin, and oxaliplatin [FOLFOX]) is an uncommon life-threatening complication and it is induced by oxaliplatin. We report a case of multiple cancers in a patient with SSc and aggravated interstitial lung disease by chemotherapy.

Keywords

References

  1. Hassoun PM. Lung involvement in systemic sclerosis. Presse Med 2011;40(1 Pt 2):e3-17. https://doi.org/10.1016/j.lpm.2010.09.015
  2. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995;76:910-4. https://doi.org/10.1002/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T
  3. Kang KY, Yim HW, Kim IJ, Yoon JU, Ju JH, Kim HY, et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol 2009;38:299-303. https://doi.org/10.1080/03009740802642062
  4. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. https://doi.org/10.1056/NEJMoa032709
  5. Jeon HJ, Woo JH, Lee HY, Park KJ, Choi HJ. Adjuvant chemotherapy using the FOLFOX regimen in colon cancer. J Korean Soc Coloproctol 2011;27:140-6. https://doi.org/10.3393/jksc.2011.27.3.140
  6. Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol 2010;21:2005-10. https://doi.org/10.1093/annonc/mdq061
  7. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, et al. Harrison's principles of internal medicine. 18th ed. New York: McGrow Hill; 2012.
  8. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44. https://doi.org/10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U
  9. Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2006;45:1012-5. https://doi.org/10.1093/rheumatology/kei281
  10. Pearson JE, Silman AJ. Risk of cancer in patients with scleroderma. Ann Rheum Dis 2003;62:697-9. https://doi.org/10.1136/ard.62.8.697
  11. Siau K, Laversuch CJ, Creamer P, O'Rourke KP. Malignancy in scleroderma patients from south west England: a populationbased cohort study. Rheumatol Int 2011;31:641-5. https://doi.org/10.1007/s00296-009-1348-y